KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Equity Average (2016 - 2026)

Teva Pharmaceutical Industries (TEVA) has disclosed Equity Average for 18 consecutive years, with $8.1 billion as the latest value for Q1 2026.

  • Quarterly Equity Average rose 38.57% to $8.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.1 billion through Mar 2026, up 38.57% year-over-year, with the annual reading at $6.6 billion for FY2025, 1.57% down from the prior year.
  • Equity Average for Q1 2026 was $8.1 billion at Teva Pharmaceutical Industries, up from $7.6 billion in the prior quarter.
  • The five-year high for Equity Average was $10.8 billion in Q1 2022, with the low at $5.8 billion in Q1 2025.
  • Average Equity Average over 5 years is $7.9 billion, with a median of $7.8 billion recorded in 2023.
  • The sharpest move saw Equity Average decreased 25.66% in 2025, then surged 38.57% in 2026.
  • Teva Pharmaceutical Industries' Equity Average stood at $9.1 billion in 2022, then fell by 14.31% to $7.8 billion in 2023, then dropped by 24.17% to $5.9 billion in 2024, then increased by 28.91% to $7.6 billion in 2025, then rose by 6.45% to $8.1 billion in 2026.
  • Per Business Quant, the three most recent readings for TEVA's Equity Average are $8.1 billion (Q1 2026), $7.6 billion (Q4 2025), and $7.0 billion (Q3 2025).